GERON CORP Debt Securities, Available-for-sale, Amortized Cost
GERON CORP (GERN) had Debt Securities, Available-for-sale, Amortized Cost of $421.79 million as of 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2025-02-27
- 2024-12-31: Debt Securities, Available-for-sale, Amortized Cost $421.79M.
- 2024-09-30: Debt Securities, Available-for-sale, Amortized Cost $315.74M.
- 2024-06-30: Debt Securities, Available-for-sale, Amortized Cost $312.79M.
- 2024-03-31: Debt Securities, Available-for-sale, Amortized Cost $274.33M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2024-12-31 | $421.79M 10-K · filed 2025-02-27 |
| 2024-09-30 | $315.74M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $312.79M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $274.33M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $306.78M 10-K · filed 2025-02-27 |
| 2023-09-30 | $351.60M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $343.71M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $296.20M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $116.14M 10-K · filed 2024-02-28 |
| 2022-09-30 | $134.32M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $144.01M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $147.00M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $177.68M 10-K · filed 2023-03-16 |
| 2021-09-30 | $186.43M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $181.48M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $212.74M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $249.66M 10-K · filed 2022-03-10 |
| 2020-09-30 | $228.26M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $241.92M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $112.97M 10-Q · filed 2020-05-28 |
| 2019-12-31 | $145.20M 10-K · filed 2021-03-11 |
| 2019-09-30 | $138.03M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $143.99M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $162.95M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $171.48M 10-K · filed 2020-03-12 |
| 2018-09-30 | $171.88M 10-Q · filed 2018-11-01 |
| 2017-12-31 | $92.80M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |